MJA
MJA InSight
MJA Careers
Letters

Hydroxychloroquine retinopathy: screening needed to prevent blindness

Elvis Ojaimi, Robyn H Guymer, Tien Y Wong and C Alex Harper
Med J Aust 2010; 192 (11): 668-669.

To the Editor: Hydroxychloroquine is used infrequently (in less than 0.1% of Australians) for the long-term management of chronic conditions (eg, rheumatoid arthritis).1 Hydroxychloroquine retinopathy is a rare but sight-threatening side effect that is usually not reversible.2-

Elvis Ojaimi, Ophthalmologist1,2
Robyn H Guymer, Head of Macular Research Unit1,2
Tien Y Wong, Head of Retinal Vascular Research Unit1,2
C Alex Harper, Head of Medical Retina Unit1,2
1 Medical Retinal Clinic, Royal Victorian Eye and Ear Hospital, Melbourne, VIC.
2 Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC.
Article References: 
Reference Order: 
1
PubMed ID: 
Reference Text: 
Gass JDM. Stereoscopic atlas of macular diseases: diagnosis and treatment. 4th ed. St Louis: CV Mosby Company, 1997.
Reference Order: 
2
PubMed ID: 
Reference Text: 
Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006; 12: 294-304.
Reference Order: 
3
PubMed ID: 
16912357
Reference Text: 
Royal College of Ophthalmologists. Hydroxychloroquine and ocular toxicity. Recommendations on screening. October 2009. London: RCO, 2009. http://www.rcophth.ac.uk/docs/publications/published-guidelines/Hydroxychloroquine_and_Ocular_Toxicity_final_Oct_2009.pdf (accessed Apr 2010).
Reference Order: 
4
PubMed ID: 
Reference Text: 
Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109: 1377-1382.
Reference Order: 
5
PubMed ID: 
12093666

The full contents of this page are only available to subscribers.